Compare AbbVie Inc (ABBV) vs Dropbox Inc (DBX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Dropbox Inc — how do they compare? AbbVie Inc trades at $253.67 (market cap $449.91B), while Dropbox Inc trades at $28.82 (market cap $6.73B). The key difference: AbbVie Inc is far larger — about 66.9× Dropbox Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Dropbox Inc pays none. Which is the better fit depends on your goals.
| ABBV | DBX | |
|---|---|---|
Market Cap | $449.91B | $6.73B |
Sector | Health | Technology |
52-Week High | $261.07 | $32.17 |
52-Week Low | $184.85 | $22.06 |
Enterprise Value | $513.38B | $9.45B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
DBX trades at $28.85, up 1.02% today, with a bullish technical signal from moving averages and a consensus price target of $30.00. The company maintains strong profitability with a net income margin of 18.71% and has beaten earnings estimates for three consecutive quarters. Recent developments include a new $900 million stock repurchase program and CEO transition news from Reuters on 2026-05-26.
Outlook remains positive with steady revenue near $2.5 billion and robust cash flow, though risks include high debt levels and competitive pressures. The stock offers moderate upside to the price target with support from buybacks, but investors should monitor execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →
